Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers

Ardelyx, Inc. reports financial results for the quarter ended December 31, 2016.

Analysis

  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -31.28 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • ARDX-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were up this period to 200.82 million compared to 107.00 million in the same period last year.
  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 33.12%.
  • All 6 peers for the company have an outstanding debt balance.
  • Net income of -31.28 million this period compared to a net income of -29.03 million last period. This is a growth of -7.73% over the previous period. In comparison, the peer group grew at 1.28%

Access our Ratings and Scores for Ardelyx, Inc.

Earnings Growth QOQ %
Cash & ST Investments

Access our Ratings and Scores for Ardelyx, Inc.

Company Profile

Ardelyx, Inc. operates as a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, tract to treat gastrointestinal and cardio-renal diseases. The company’s products include Tenapanor, RDX002, RDX009 and RDX013. Ardelyx was founded by Dominique Charmot, Peter G. Schultz and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ARDX-US.